Literature DB >> 15526177

[Therapeutic management of intra-abdominal and retroperitoneal soft tissue sarcomas].

S Wong1, M F Brennan.   

Abstract

In this article, we review the diagnostics, therapy, follow-up, and prognosis of intra-abdominal and retroperitoneal soft tissue sarcomas. There are descriptions and discussion of the surgical techniques, advantages and disadvantages of various types and combinations of adjuvant and neoadjuvant therapies, therapy in case of nonresectability, and procedures for desmoid tumors. Further, treatment results, control methods, and studies on new therapeutic approaches are presented.

Entities:  

Mesh:

Year:  2004        PMID: 15526177     DOI: 10.1007/s00104-004-0961-2

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  23 in total

Review 1.  Intensity modulated radiation therapy: a clinical review.

Authors:  C Nutting; D P Dearnaley; S Webb
Journal:  Br J Radiol       Date:  2000-05       Impact factor: 3.039

2.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer.

Authors:  K M Tveit
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

3.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Is there a role for incomplete resection in the management of retroperitoneal liposarcomas?

Authors:  D Shibata; J J Lewis; D H Leung; M F Brennan
Journal:  J Am Coll Surg       Date:  2001-10       Impact factor: 6.113

5.  Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.

Authors:  Jean-Michel Coindre; Odette Mariani; Frédéric Chibon; Aline Mairal; Nicolas De Saint Aubain Somerhausen; Elizabeth Favre-Guillevin; Nguyen Binh Bui; Eberhard Stoeckle; Isabelle Hostein; Alain Aurias
Journal:  Mod Pathol       Date:  2003-03       Impact factor: 7.842

6.  Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum.

Authors:  J Glenn; W F Sindelar; T Kinsella; E Glatstein; J Tepper; J Costa; A Baker; P Sugarbaker; M F Brennan; C Seipp
Journal:  Surgery       Date:  1985-03       Impact factor: 3.982

Review 7.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

8.  Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

Authors:  Samuel Singer; Cristina R Antonescu; Elyn Riedel; Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 9.  Retroperitoneal sarcomas: combined modality treatment approaches.

Authors:  Peter W T Pisters; Brian O'Sullivan
Journal:  Curr Opin Oncol       Date:  2002-07       Impact factor: 3.645

Review 10.  Soft tissue sarcomas of adults: state of the translational science.

Authors:  Ernest C Borden; Laurence H Baker; Robert S Bell; Vivien Bramwell; George D Demetri; Burton L Eisenberg; Christopher D M Fletcher; Jonathan A Fletcher; Marc Ladanyi; Paul Meltzer; Brian O'Sullivan; David R Parkinson; Peter W T Pisters; Scott Saxman; Samuel Singer; Murali Sundaram; Allan T van Oosterom; Jaap Verweij; Jill Waalen; Sharon W Weiss; Murray F Brennan
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

View more
  2 in total

1.  Long-term outcome after multivisceral and tumor/vascular resection in patients with soft tissue sarcoma.

Authors:  P Vogel; U Bolder; M N Scherer; H-J Schlitt; K-W Jauch
Journal:  Langenbecks Arch Surg       Date:  2008-08-12       Impact factor: 3.445

Review 2.  [Operative therapy of abdominal and retroperitoneal sarcoma].

Authors:  M Albertsmeier; J Werner; L H Lindner; C Belka; R D Issels; M K Angele
Journal:  Chirurg       Date:  2014-05       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.